Supernus Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance on January 31, 2017 of an eighth patent by the United States Patent and Trademark Office covering Trokendi XR, its novel once-daily extended-release topiramate product. The patent provides protection for the product with expiration that is no earlier than 2027.
Category: Seizures
Families urge action on marijuana extract
Families struggling with epilepsy are telling lawmakers they’re tired of waiting for access to a marijuana extract used to treat seizures. Legislators are considering a bill from Republican Sen. Van Wanggaard that would make it legal to possess cannabidiol oil with a doctor’s certification.
In Wisconsin, signs of GOP softening on medical marijuana
As a marijuana extract used to treat seizures is more widely embraced, the conversation in Wisconsin is shifting to whether the time is right to approve medical marijuana. Assembly Speaker Robin Vos told reporters last week he would consider it, even as Republican Senate Majority Leader Scott Fitzgerald and Gov. Scott Walker say no way.
Lawmaker confident marijuana extract bill will pass
A Republican state senator plans to introduce a bill next week that would make it legal in Wisconsin to possess a marijuana extract used to treat seizures. A similar bill failed to pass last session despite widespread bipartisan support when Republican senators derailed the proposal amid concerns it would open the door to legalizing marijuana.
Neurelis Announces Finalization Of Series B Financing
Neurelis, Inc. today announced that it has finalized a Series B financing round led by HBM Healthcare Investments. In addition, LYZZ Capital, which led the Series A funding for Neurelis, has participated in the Series B round.